High Blood Pressure-Abdominal Obesity Phenotype as Indicator of Dyslipidemia and Hyperuricemia
Abstract
Introduction: The arterial hypertension-abdominal obesity phenotype is a simple and useful marker to identify patients with abdominal obesity who have altered metabolic profiles without the need to use additional laboratory tests.
Objective: To determine the usefulness of the arterial hypertension-abdominal obesity phenotype as an indicator of dyslipidemia and hyperuricemia in individuals at risk of type 2 diabetes mellitus.
Methods: A cross-sectional descriptive study was carried out with 964 adults (449 women and 515 men), who attended the Endocrinology Institute for suspected diabetes mellitus. Demographic (age, sex, skin color), clinical (blood pressure and acanthosis nigricans), anthropometric (weight, height, waist circumference and body mass index) and laboratory (glycemia, lipid profile and uric acid) variables were analyzed. The hypertension-abdominal obesity phenotype was defined as the presence of systolic pressure ≥130 mm Hg, or diastolic pressure ≥80 mm Hg, or treated hypertension, waist circumference ≥80 cm in women and ≥90 cm in men. The sensitivity, specificity and predictive values of the hypertension-abdominal obesity phenotype were calculated to identify people with hyperuricemia and dyslipidemia.
Results: Individuals with the arterial hypertension-abdominal obesity phenotype showed higher proportion of lipid alterations and hyperuricemia than people without the phenotype (p < 0.002). The arterial hypertension-abdominal obesity phenotype appropriately identifies subjects with the presence of hyperuricemia, hypercholesterolemia, hypertriglyceridemia or dyslipidemia (at least one lipid alteration), since they show sensitivities (72.7, 62.5, 68.1 and 65.6%, respectively) and negative predictive values (92.7, 69.9, 73.3 and 58.2%, respectively).
Conclusions: The hypertension-abdominal obesity phenotype is a simple and useful option to identify people with hyperuricemia and dyslipidemia.
Keywords: abdominal obesity; arterial hypertension; dyslipidemia; hyperuricemia.
Downloads
References
Referencias bibliográficas
Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-223. https://doi.org/10.1038/s41573-021-00337-8
Oussaada SM, van Galen KA, Cooiman MI, Kleinendorst L, Hazebroek EJ, van Haelst MM, et al. The pathogenesis of obesity. Metabolism. 2019;92:26-36. doi: 10.1016/j.metabol.2018.12.012.
Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021; 18: 689–700. https://doi.org/10.1038/s41569-021-00541-4
Ali N, Samadder M, Kathak RR, Islam F. Prevalence and factors associated with dyslipidemia in Bangladeshi adults. PLoS One. 2023;18(1):e0280672. doi: 10.1371/journal.pone.0280672.
Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hiperuricemia. Am J Transl Res [Internet] 2020 [citado 2024 Ene 29];12(7):3167-81. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407685/
Zhu J, Zhang Y, Wu Y, Xiang Y, Tong X, Yu Y, et al. Obesity and Dyslipidemia in Chinese Adults: A Cross-Sectional Study in Shanghai, China. Nutrients [Internet] 2022 [citado 2024 Ene 29] 14(11), 2321. https://doi.org/10.3390/nu14112321
Sangrós FJ, Torrecilla J, Giráldez-García C, Carrillo L, Mancera J, Mur T, et al. Association of general and abdominal obesity with hypertension, dyslipidemia and prediabetes in the PREDAPS Study. Rev Esp Cardiol (Engl Ed). 2018;71(3):170-177. http://dx.doi.org/10.1016/j.rec.2017.04.035
de Oliveira EP, Moreto F, Silveira LV, Burini RC. Dietary, anthropometric, and biochemical determinants of uric acid in free-living adults. Nutr J. 2013;12:11–20. doi: 10.1186/1475-2891-12-11
Madala ND, Dubula T, Assounga AGH, Naicker S. Association of kidney function and waist circumference with uric acid levels in South Africans. Metab Syndr Relat Disord. 2017;15(10):500–6. doi: 10.1089/met.2017.0025
Wang YY, Li L, Cui J, Yin F, Yang F, Yuan DM, et al.
Associations between anthropometric parameters (body mass index, waist circumference and waist to hip ratio) and newly diagnosed hyperuricemia in adults in Qingdao, China: a cross-sectional study. Asia Pac J Clin Nutr. 2020;29(4):763–70. doi: 10.6133/apjcn.202012_29(4).0011
Zhou Z, Li K, Li X, Luan R, Zhou R. Independent and joint associations of body mass index, waist circumference, waist‑height ratio and their changes with risks of hyperuricemia in middle‑aged and older Chinese individuals: a population‑based nationwide cohort study. Nutr Metab (Lond). [Internet] 2021 [cited 2024 Jan 29]; 18:62 https://doi.org/10.1186/s12986-021-00590-z
Choi D, Choi S, Son JS, Oh SW, Park SM. Impact of discrepancies in general and abdominal obesity on major adverse cardiac events. J Am Heart Assoc. 2019;8(18):e013471. doi:10.1161/JAHA.119.013471.
Wang Y, Howard AG, Adair LS, Wang H, Avery
